PatientConcept®
A modern Method for the Implementation of Risk-Management-Plans

M. Lang, M. Mayr, M. Krause, S. Ringbauer

Introduction

Modern highly effective therapies include the need to implement a detailed risk management plan (RMP). The RMP reflects the necessary monitoring of the patient. Partly, a regular control of health values in defined temporal intervals is needed. The medical app PatientConcept is applicable also on further indications such as rheumatology, diabetology, oncology, etc. Such complex fields of application require an instrument to facilitate communication between practitioner and patient while enabling controlled transposition of the therapy associated risk management plans and at the same time ensuring strict compliance of data security.

Methods

PatientConcept is an app-based digital system for therapy assistance and monitoring, which meets all previously mentioned requirements. Secure communication by mobile app between practitioner and patient is enabled by an unique identity code. The assigned specifications of the respective risk management plan are monitored by the system. PatientConcept is a professional, practice individualized, multilingual and CE certified digital system.

Results

Evaluation in the fields of MS has shown that PatientConcept enables the safe transmission of encrypted personal health-related data. An automated reconciliation of the data transferred allows a safe digital treatment monitoring. Long-term sequences of appointments can be organized by the system and thus may result in a reduction of time and effort for the practice staff but at the same time increase the frequency of contacts to the patient. Thereby, an improvement of adherence is made possible.

Discussion and conclusions

An improvement of therapeutic safety of patients in long-term treatment is made possible by the application of a digital system for therapy monitoring and assistance. The utilization of PatientConcept for patients with MS has shown positive results, therefore the system should be as well evaluated for other indications.

Disclosure and declaration of interest:

M. Lang and M. Krause have received travel grants, speaker's honoraria, financial research support, consultancy fees from Teva, Merck Serono, Genzyme -Sanofi, Novartis, Bayer, Biogen, Roche.
S. Ringbauer and M. Mayr have nothing to disclose.